These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14600520)

  • 1. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
    Gruzdev B; Rakhmanova A; Doubovskaya E; Yakovlev A; Peeters M; Rinehart A; de Dier K; Baede-Van Dijk P; Parys W; van 't Klooster G
    AIDS; 2003 Nov; 17(17):2487-94. PubMed ID: 14600520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
    Sankatsing SU; Weverling GJ; Peeters M; van't Klooster G; Gruzdev B; Rakhmanova A; Danner SA; Jurriaans S; Prins JM; Lange JM
    AIDS; 2003 Dec; 17(18):2623-7. PubMed ID: 14685056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
    Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
    HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Lazzarin A; Campbell T; Clotet B; Johnson M; Katlama C; Moll A; Towner W; Trottier B; Peeters M; Vingerhoets J; de Smedt G; Baeten B; Beets G; Sinha R; Woodfall B;
    Lancet; 2007 Jul; 370(9581):39-48. PubMed ID: 17617271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
    ; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
    AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
    Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
    Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
    AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
    Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
    AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.
    Gazzard BG; Pozniak AL; Rosenbaum W; Yeni GP; Staszewski S; Arasteh K; De Dier K; Peeters M; Woodfall B; Stebbing J; vant' Klooster GA
    AIDS; 2003 Dec; 17(18):F49-54. PubMed ID: 14685068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.
    Cahn P; Cassetti I; Wood R; Phanuphak P; Shiveley L; Bethell RC; Sawyer J
    AIDS; 2006 Jun; 20(9):1261-8. PubMed ID: 16816554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
    Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
    AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
    Floris-Moore MA; Mollan K; Wilkin AM; Johnson MA; Kashuba AD; Wohl DA; Patterson KB; Francis O; Kronk C; Eron JJ
    Antivir Ther; 2016; 21(1):55-64. PubMed ID: 26263403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.